2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Arthritis & Rheumatology2015Vol. 68(1), pp. 1–26
Citations Over TimeTop 1% of 2015 papers
Jasvinder A. Singh, Kenneth G. Saag, S. Louis Bridges, Elie A. Akl, Raveendhara R. Bannuru, Matthew C. Sullivan, Elizaveta E. Vaysbrot, Christine McNaughton, Mikala C. Osani, Robert H. Shmerling, Jeffrey R. Curtis, Daniel E. Furst, Deborah Parks, Arthur Kavanaugh, James R. O’Dell, Charles M. King, Amye Leong, Eric L. Matteson, John T. Schousboe, Barbara E. Drevlow, Seth Ginsberg, Jacques Grober, E. William St. Clair, Elizabeth A. Tindall, Amy S. Miller, Timothy E. McAlindon
Abstract
This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.
Related Papers
- → Therapies for Active Rheumatoid Arthritis after Methotrexate Failure(2013)373 cited
- → Higher Dose of Tofacitinib for Rheumatoid Arthritis Poses Risks(2019)2 cited
- → Economic Evaluation Of Tofacitinib Compared With Biological Therapy As Initial Medication After Failure To Methotrexate In Adults With Rheumatoid Arthritis In Colombia(2014)1 cited
- → Does treatment with glucocorticoids or with disease-modifying antirheumatic drugs reduce the rate of radiographic progression in rheumatoid arthritis? Comment on the article by Abu-Shakra et al(1999)
- → What is the effect of adding a disease-modifying antirheumatic drug (DMARD) to methotrexate (MTX) for people with rheumatoid arthritis and an inadequate response to MTX alone?(2020)